vs
林德（LIN）与美敦力（MDT）财务数据对比。点击上方公司名可切换其他公司
美敦力的季度营收约是林德的1.0倍（$9.0B vs $8.8B），美敦力同比增速更快（8.7% vs 8.2%），美敦力自由现金流更多（$3.3B vs $898.0K），过去两年林德的营收复合增速更高（3.1% vs 2.5%）
林德是全球知名跨国化工企业，按市场份额及营收计为全球最大工业气体供应商。公司1879年由德国科学家、工程师卡尔·冯·林德在德国威斯巴登创立，现总部位于英国沃金，在爱尔兰注册，2018年由原林德股份公司与1907年在美国成立的普莱克斯合并组建。
美敦力是全球知名的医疗设备企业，法定及行政总部位于爱尔兰，运营总部设在美国明尼苏达州明尼阿波利斯。2015年集团收购爱尔兰企业柯惠后将注册地迁至爱尔兰，目前业务覆盖超150个国家，员工逾9万名，专注于研发生产各类医疗技术产品及治疗解决方案。
LIN vs MDT — 直观对比
营收规模更大
MDT
是对方的1.0倍
$8.8B
营收增速更快
MDT
高出0.5%
8.2%
自由现金流更多
MDT
多$3.3B
$898.0K
两年增速更快
LIN
近两年复合增速
2.5%
损益表 — Q1 FY2026 vs Q4 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $8.8B | $9.0B |
| 净利润 | — | $1.1B |
| 毛利率 | 48.5% | — |
| 营业利润率 | 27.8% | 16.2% |
| 净利率 | — | 12.8% |
| 营收同比 | 8.2% | 8.7% |
| 净利润同比 | — | -11.7% |
| 每股收益（稀释后） | $3.98 | $0.89 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LINMDT
| Q1 26 | $8.8B | $9.0B | ||
| Q4 25 | $8.8B | $9.0B | ||
| Q3 25 | $8.6B | $8.6B | ||
| Q2 25 | $8.5B | $8.9B | ||
| Q1 25 | $8.1B | $8.3B | ||
| Q4 24 | $8.3B | $8.4B | ||
| Q3 24 | $8.4B | $7.9B | ||
| Q2 24 | $8.3B | $8.6B |
净利润LINMDT
| Q1 26 | — | $1.1B | ||
| Q4 25 | $1.5B | $1.4B | ||
| Q3 25 | $1.9B | $1.0B | ||
| Q2 25 | $1.8B | $1.1B | ||
| Q1 25 | $1.7B | $1.3B | ||
| Q4 24 | $1.7B | $1.3B | ||
| Q3 24 | $1.6B | $1.0B | ||
| Q2 24 | $1.7B | $654.0M |
毛利率LINMDT
| Q1 26 | 48.5% | — | ||
| Q4 25 | — | 65.8% | ||
| Q3 25 | — | 65.0% | ||
| Q2 25 | — | 64.8% | ||
| Q1 25 | — | 66.5% | ||
| Q4 24 | — | 64.9% | ||
| Q3 24 | — | 65.1% | ||
| Q2 24 | — | 64.5% |
营业利润率LINMDT
| Q1 26 | 27.8% | 16.2% | ||
| Q4 25 | 23.0% | 18.8% | ||
| Q3 25 | 27.5% | 16.8% | ||
| Q2 25 | 27.7% | 16.1% | ||
| Q1 25 | 26.9% | 19.9% | ||
| Q4 24 | 27.4% | 19.0% | ||
| Q3 24 | 25.0% | 16.1% | ||
| Q2 24 | 26.4% | 12.3% |
净利率LINMDT
| Q1 26 | — | 12.8% | ||
| Q4 25 | 17.5% | 15.3% | ||
| Q3 25 | 22.4% | 12.1% | ||
| Q2 25 | 20.8% | 11.8% | ||
| Q1 25 | 20.6% | 15.6% | ||
| Q4 24 | 20.8% | 15.1% | ||
| Q3 24 | 18.5% | 13.2% | ||
| Q2 24 | 20.1% | 7.6% |
每股收益（稀释后）LINMDT
| Q1 26 | $3.98 | $0.89 | ||
| Q4 25 | $3.28 | $1.07 | ||
| Q3 25 | $4.09 | $0.81 | ||
| Q2 25 | $3.73 | $0.81 | ||
| Q1 25 | $3.51 | $1.01 | ||
| Q4 24 | $3.61 | $0.99 | ||
| Q3 24 | $3.22 | $0.80 | ||
| Q2 24 | $3.44 | $0.50 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $4.0B | — |
| 总债务越低越好 | $24.7B | — |
| 股东权益账面价值 | $40.1B | — |
| 总资产 | $86.3B | — |
| 负债/权益比越低杠杆越低 | 0.62× | — |
8季度趋势，按日历期对齐
现金及短期投资LINMDT
| Q1 26 | $4.0B | — | ||
| Q4 25 | $5.1B | $8.3B | ||
| Q3 25 | $4.5B | $8.1B | ||
| Q2 25 | $4.8B | $9.0B | ||
| Q1 25 | $5.3B | $7.9B | ||
| Q4 24 | $4.8B | $8.0B | ||
| Q3 24 | $5.2B | $7.8B | ||
| Q2 24 | $4.6B | $8.0B |
总债务LINMDT
| Q1 26 | $24.7B | — | ||
| Q4 25 | $20.7B | $27.7B | ||
| Q3 25 | $18.6B | $26.2B | ||
| Q2 25 | $19.7B | $25.6B | ||
| Q1 25 | $17.6B | $24.0B | ||
| Q4 24 | $15.3B | $24.6B | ||
| Q3 24 | $17.5B | $26.3B | ||
| Q2 24 | $16.9B | $23.9B |
股东权益LINMDT
| Q1 26 | $40.1B | — | ||
| Q4 25 | $38.2B | $48.7B | ||
| Q3 25 | $38.6B | $47.9B | ||
| Q2 25 | $38.5B | $48.0B | ||
| Q1 25 | $38.0B | $49.4B | ||
| Q4 24 | $38.1B | $48.5B | ||
| Q3 24 | $39.2B | $47.9B | ||
| Q2 24 | $38.2B | $50.2B |
总资产LINMDT
| Q1 26 | $86.3B | — | ||
| Q4 25 | $86.8B | $91.3B | ||
| Q3 25 | $86.0B | $91.0B | ||
| Q2 25 | $86.1B | $91.7B | ||
| Q1 25 | $82.7B | $90.0B | ||
| Q4 24 | $80.1B | $90.0B | ||
| Q3 24 | $82.5B | $89.7B | ||
| Q2 24 | $80.2B | $90.0B |
负债/权益比LINMDT
| Q1 26 | 0.62× | — | ||
| Q4 25 | 0.54× | 0.57× | ||
| Q3 25 | 0.48× | 0.55× | ||
| Q2 25 | 0.51× | 0.53× | ||
| Q1 25 | 0.46× | 0.49× | ||
| Q4 24 | 0.40× | 0.51× | ||
| Q3 24 | 0.45× | 0.55× | ||
| Q2 24 | 0.44× | 0.48× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $4.8B |
| 自由现金流经营现金流 - 资本支出 | $898.0K | $3.3B |
| 自由现金流率自由现金流/营收 | 0.0% | 37.1% |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | 4.14× |
| 过去12个月自由现金流最近4个季度 | $4.2B | $6.5B |
8季度趋势，按日历期对齐
经营现金流LINMDT
| Q1 26 | — | $4.8B | ||
| Q4 25 | $3.0B | $925.0M | ||
| Q3 25 | $2.9B | $1.1B | ||
| Q2 25 | $2.2B | $2.5B | ||
| Q1 25 | $2.2B | $2.6B | ||
| Q4 24 | $2.8B | $958.0M | ||
| Q3 24 | $2.7B | $986.0M | ||
| Q2 24 | $1.9B | $2.8B |
自由现金流LINMDT
| Q1 26 | $898.0K | $3.3B | ||
| Q4 25 | $1.6B | $457.0M | ||
| Q3 25 | $1.7B | $584.0M | ||
| Q2 25 | $954.0M | $2.1B | ||
| Q1 25 | $891.0M | $2.1B | ||
| Q4 24 | $1.6B | $554.0M | ||
| Q3 24 | $1.7B | $466.0M | ||
| Q2 24 | $796.0M | $2.4B |
自由现金流率LINMDT
| Q1 26 | 0.0% | 37.1% | ||
| Q4 25 | 17.9% | 5.1% | ||
| Q3 25 | 19.4% | 6.8% | ||
| Q2 25 | 11.2% | 23.2% | ||
| Q1 25 | 11.0% | 25.3% | ||
| Q4 24 | 18.8% | 6.6% | ||
| Q3 24 | 19.9% | 5.9% | ||
| Q2 24 | 9.6% | 27.4% |
资本支出强度LINMDT
| Q1 26 | — | — | ||
| Q4 25 | 16.6% | 5.2% | ||
| Q3 25 | 14.8% | 5.9% | ||
| Q2 25 | 14.8% | 5.1% | ||
| Q1 25 | 15.7% | 5.7% | ||
| Q4 24 | 15.1% | 4.8% | ||
| Q3 24 | 12.8% | 6.6% | ||
| Q2 24 | 13.7% | 5.0% |
现金转化率LINMDT
| Q1 26 | — | 4.14× | ||
| Q4 25 | 1.98× | 0.67× | ||
| Q3 25 | 1.53× | 1.05× | ||
| Q2 25 | 1.25× | 2.39× | ||
| Q1 25 | 1.29× | 1.99× | ||
| Q4 24 | 1.63× | 0.75× | ||
| Q3 24 | 1.76× | 0.95× | ||
| Q2 24 | 1.16× | 4.25× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LIN
暂无分部数据
MDT
| Cardiovascular Portfolio | $3.5B | 38% |
| Neuroscience Portfolio | $2.6B | 28% |
| Medical Surgical Portfolio | $2.2B | 24% |
| Diabetes business | $796.0M | 9% |
